Trial Profile
Analysis of Circulating Tumor Markers in the Blood
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Everolimus; Fulvestrant; Palbociclib
- Indications Advanced breast cancer; Bone cancer; Colorectal cancer; HER2 positive breast cancer; Lung cancer; Non-small cell lung cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer; Uveal melanoma
- Focus Biomarker; Proof of concept; Therapeutic Use
- Acronyms ALCINA
- 16 Nov 2023 Results assessing prognostic value of three liquid biopsy analytes (CTCs, sEVs, and ctDNA), alone and in combination in patient samples (n=54) from this study published in the British Journal of Cancer.
- 05 Sep 2023 Planned End Date changed from 1 Jul 2024 to 1 Sep 2025.
- 05 Sep 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Sep 2024.